Revolution Medicines escalated its daraxonrasib momentum at AACR, reporting updated first-line metastatic pancreatic ductal adenocarcinoma (PDAC) data across monotherapy and combination cohorts. The company is advancing a next-generation approach to RAS biology with an oral, RAS(ON) multi-selective inhibitor, positioning daraxonrasib for broader impact beyond second-line settings. Separate results highlighted at the meeting follow Revolution’s earlier phase III readout in previously treated metastatic PDAC, where the company said median overall survival approached 13.2 months versus 6.7 months with chemotherapy. Analysts and clinicians cited the magnitude of the survival improvement as a key signal that RAS-directed strategies may be shifting from exploratory to clinically durable. With first-line data now in focus, attention also shifts to sequencing and genotype coverage across trials. Revolution’s phase III program (RASolute 303) is designed to enroll PDAC patients regardless of tumor RAS genotype, which—if confirmed in later analyses—could broaden treatment eligibility beyond narrow molecular subsets.